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A bioequivalence study was proved of generic Febuxostat 80 mg tablets (T) in healthy volunteers.For this purpose,
Authors developed a simple, sensitive, selective, rapid, rugged and reproducible liquid chromatography–tandem
mass spectrometry method for the quantification of Febuxostat (FB) in human plasma using Febuxostat D7 (FBD7)
as an internal standard (IS) was used. Chromatographic separation was performed on Ascentis Express C18
(50x4.6 mm, 3.5 μ) column. Mobile phase composed of 10 mM Ammonium formate: Acetonitrile (20:80 v/v), with
0.8 mL/min flow-rate. Drug and IS were extracted by Liquid- liquid extraction. FB and FBD7 were detected with
proton adducts at m/z 317.1→261.1 and 324.2→262.1 in multiple reaction monitoring (MRM) positive mode
respectively. The method was validated with the correlation coefficients of (r2) ≥ 0.9850 over a linear concentration
range of 1.00-8000.00 ng/mL. This method demonstrated intra and inter-day precision within 2.64 to 3.88 and 2.76
to 8.44% and accuracy within 97.33 to 99.05 and 100.30 to 103.19% for FB. This method is successfully applied in
the Bioequivalence study of 9 human volunteers.
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Febuxostat is chemically 2-(3-cyano-4-isobutoxyphenyl)-4-
methyl-1,3- thiazole-5- carboxylic acid. It is available in the
form non hygroscopic crystalline nature and freely soluble
in dimethylformamide, soluble in dimethylsulfide, spar-
ingly soluble in ethanol, slightly soluble in methanol and
acetonitrile, and practically insoluble in water (Tayar et al.
2012; Hussar & Bilbow 2009; Tomillero & Moral 2009).
Febuxostat is orally administered a non-purine, selective
inhibitor of xanthine oxidase being developed for the
management of hyperuricaemia in patients with gout
(Zhu et al. 2009; Hoshide et al. 2004; Becker et al. 2005;
Grabowski BA, et al. 2011; Kamatani N, et al. 2011;). The
molecular formula is C16H16N2O3S (Figure 1). Febuxostat,
is available in two dosage strengths; 40 mg and 80 mg. The
absorption of radiolabeled Febuxostat following oral dose
administration was estimated to be at least 49% (based on* Correspondence: kanchanareddy1@gmail.com
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in any medium, provided the original work is ptotal radioactivity recovered in urine). Maximum plasma
concentrations of Febuxostat occurred between 1 to
1.5 hours post-dose. After multiple oral 40 mg and 80 mg
once daily doses, Cmax is approximately 1.6 ± 0.6 mcg per
mL (N = 30), and 2.6 ± 1.7 mcg per mL (N = 227), respect-
ively. Absolute bioavailability of the Febuxostat tablet has
not been studied. Following multiple 80 mg once daily
doses with a high fat meal, there was a 49% decrease in
Cmax and an 18% decrease in AUC, respectively. However,
no clinically significant change in the percent decrease in
serum uric acid concentration was observed (58% fed vs.
51% fasting). The mean apparent steady state volume of
distribution (VSS/F) of Febuxostat was approximately 50 L
(CV ~40%). The plasma protein binding of Febuxostat is
approximately 99.2%, (primarily to albumin), and is con-
stant over the concentration range achieved with 40 mg
and 80 mg doses. Febuxostat is extensively metabolized by
liverand eliminated by both hepatic and renal pathways.
The apparent mean terminal elimination half-life (t1/2) of
Febuxostat was approximately 5 to 8 hours (Khosravan R
et al. 2012;).an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Chemical structures of Febuxostat and Febuxostat-d7.
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were reported for quantification of Febuxostat by using
UV (Bagga et al. 2011; Sheth et al. 2012), Liquid chro-
matography (LC) (Gunda et al. 2012a; Kumaraswamy
Gandla et al. 2012; Cong et al. 2010; Naresh Chandra
Reddy & Chandra Sekhar 2012; Nageswara Rao et al. 2012;
Gunda et al. 2012b; Muvvala1 et al. 2012; Yamamoto et al.
1995; Menon et al. 2011; Mathrusri Annapurna et al. 2012),
UPLC (Sahu et al. 2012), UPLC-MS (Lukram et al. 2012;
Zhang et al. 2012). Liquid chromatography -Mass spec-
trometry (LC) (Kadivar et al. 2011; Ding et al. 2012;
Wang et al. 2012). These methods have been reported for
the quantitative estimation of Febuxostat in pharmaceu-
tical (Bagga et al. 2011; Sheth et al. 2012; Gunda et al.
2012a; Kumaraswamy Gandla et al. 2012; Cong et al.
2010; Naresh Chandra Reddy & Chandra Sekhar 2012;
Nageswara Rao et al. 2012; Gunda et al. 2012b; Muvvala1
et al. 2012; Sahu et al. 2012; Kadivar et al. 2011) and bio-
logical fluids (Yamamoto et al. 1995; Menon et al. 2011;
Lukram et al. 2012; Zhang et al. 2012; Ding et al. 2012;
Wang et al. 2012). Among all Quantification of Febuxostat
in biological matrices by using LC-MS/MS (Ding et al.
2012; Wang et al. 2012) were reported. Xitao ding et.al
(Ding et al. 2012) developed the method in rat plasma
using protein precipitation extraction method by using
acetonitrile as an precipitating agent. They developed with
the linearity range of 10–2000 ng/mL for Febuxostat and
used midazolam as internal standard and applied to deter-
minate of Febuxostat in rat plasma for pharmacokinetic
study. Wang H et.al. (2012) developed the method in hu-
man plasma using protein precipitation extraction method
by using acetonitrile as an precipitating agent. They devel-
oped the method with linear range of 10.00-5000.00 ng/mL
for Febuxostat and used Febuxostat-d7 as an internal stan-
dard and performed the pharmacokinetic study in healthy
chinese volunteers.
However LC-MS/MS has gained importance for the
quantitative estimation of drugs in various biological
matrices including plasma, serum, urine, and ocular fluids,
due to its high sensitivity, selectivity and reproducibility.
The published methods (Ding et al. 2012; Wang et al.
2012) are precipitation methods by using LC-MS. Preci-pitation method has some disadvantages rather than
Liquid-liquid extraction in-terms of extraction efficacy,
matrix effect. The aim of the proposed method is extrac-
tion of Febuxostat in human plasma by Liquid-liquid
extraction method and used internal standard as deuter-
ated compound Febuxostat–d7. The proposed method is
most simple, highly sensitive, wide linear and high selec-
tive extraction method with good recovery, fully validated
as per FDA guidelines and was successfully applied in




Febuxostat obtained from AMI Life sciences Pvt.Lt.D
Baroda,Gujarat India and Febuxostat D7 Obtained from
Euroasian Chemicals Pvt.Ltd, Mumbai , India. HPLC
grade methanol, Acetonitrile were purchased from Jt.
Baker Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA.
Ammonium formate, Formic acid was purchased from
S.D fine chemicals Mumbai. Methyl t-butyl ether was
purchased from Merck speciality private limited, worli,
Mumbai. Ultra pure water from Milli-Q system
(Millipore, Bedford, MA, USA) was used through the
study. All other chemicals in this study were of analytical
grade.Human plasma was obtained from Doctors patho-
logical lab , Hyderabad.
Drugs
The reference Urolac® immediate release tablet formulation
was manufactured by Takeda Pharmaceuticals, America,
INC (USA), (batch number R1785, manufacture date Jun
07, 2011, and expiry date Jun 07, 2013). The test formu-
lation was manufactured byAPL Research center. Each im-
mediate release tablet of both formulations contained
Febuxostat equivalent to 80 mg. The clinical study was
conducted at Clinical and Pharmacological Research Unit,
Acron Accunova, Manipal.
Instrumentation
HPLC system (1200 Series Agilent Technologies, Germany)
connected with triple quadrupole mass spectrometer in-
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was performed with the Analyst 1.4.1 software package
(SCIEX). Ionization was performed by Electro spray posi-
tive mode with Unit Resolution.
Detection
Mass parameters were optimized to get the product ions
of m/z: 261.1, m/z: 262.1 from its respective precursor
ions of FB [M +H]+ (m/z: 317.1) and FBD7 [M +H]+
(m/z: 324.2) with Source temperature 500°C, Ion Spray
voltage 5500 volts, Heater gas, Nebulizer gas 30 psi each,
Curtain gas 20 psi, CAD gas 6 psi, (all gas channels with
nitrogen) Source flow rate 500 μL/min without split, En-
trance potential 10 V, Declustering potential 45 V for an-
alyte and 55 V for internal standard, Collision energy
28 V for both analyte and internal standard, Collision
cell exit potential 12 V for analyte and 14 V for internal
standard.
Chromatographic conditions
Chromatography was performed on Ascentis Express
C18 (50x4.6 mm, 3.5 μ) analytical column at 40°C, with
10 mM Ammonium formate: Acetonitrile (20:80 v/v) as
mobile phase at a flow rate of 0.8 mL/min. FBD7 was
used as an internal standard in terms of chromatography
and extractability. The drug and internal standard was
eluted at 0.6 ± 0.2 min with 2.5 min total run time.
Preparation of standards and quality control (QC) samples
Standard stock solutions of FB (1000.00 μg/mL) and
FBD7 (100.00 μg/mL) was prepared in methanol. The in-
ternal standard spiking solution (1000.00 ng/mL) was
prepared in 50% acetonitrile from FBD7 standard stock
solution (100.00 μg/mL). Standard stock solutions and
Internal standard spiking solutions were stored in re-
frigerator conditions (2–8°C) until analysis. Standard
stock solution of FB was added to screened drug-free
human plasma to obtain concentration levels of 1.00,
2.00, 20.00, 100.00, 200.00, 400.00, 1000.00, 3000.00,
6000.00, and 8000.00 ng/mL for analytical standards and
1.00, 3.00, 4000.00, 4800.00 ng/mL for Quality control
standards and stored in a −30°C freezer until analysis.
Respective aqueous standards were prepared in reconsti-
tution solution (10 mM ammonium formate: acetonitrile
(20:80) and stored in refrigerator conditions 2–8°C until
analysis.
Sample preparation
Liquid-liquid extraction was used to isolate drug and IS
from human plasma. For this purpose, 100 μL of IS
(1000.00 ng/mL) and 100 μL of plasma sample (respec-
tive concentration) was added into labeled polypropylene
tubes and vortexed briefly. Followed by, 100 μL of 0.1%formic acid, 2.0 mL of extraction solvent (methyl tertiary
butyle ether) were added and vortexed for 10 min. Then
the samples were centrifuged at 4000 rpm for 5 min at
20°C temperature. Subsequently, the supernatant from
each sample was transferred into respective polypropy-
lene tubes. After that, all the samples were kept for
evaporation under nitrogen at 40°C. The dried residue
was reconstituted with 1000 μL of reconstitution solu-
tion and vortexed briefly. Finally, the extracted sample
was transferred into auto sampler vials and injected into
LC-MS/MS.
Selectivity and specificity
The selectivity of the method was determined by six
different human blank plasma samples, which were
pretreated and analyzed to test the potential interfer-
ences of endogenous compounds co-eluting with ana-
lyte and IS. Chromatographic peaks of analyte and IS
were identified based on their retention times and
MRM responses. The peak area of FB at the respective
retention time in blank samples should not be more
than 20% of the mean peak area of LOQ of FB. Simi-
larly, the peak area of FBD7 at the respective retention
time in blank samples should not be more than 5% of
the mean peak area of LOQ of FBD7.
Recovery
The extraction recovery of FB and FBD7 from human
plasma was determined by analyzing quality control sam-
ples. Recovery at three concentrations (30.00, 4000.00,
and 4800.00 ng/mL) was determined by comparing peak
areas obtained from the plasma sample and the standard
solution spiked with the blank plasma residue. A recovery
of more than 85% was considered adequate to obtain re-
quired recovery.
Limit of detection (LOD) and limit of quantification (LOQ)
The limit of detection (LOD) is a parameter that provides
the lowest concentration in a sample that can be detected
from background noise but not quantitated. LOD was de-
termined using the signal-to-noise ratio (s/n) of 3:1 by
comparing test results from samples with known concen-
trations of analytes with blank samples.
The limit of quantitation (LOQ) is defined as the low-
est concentration of analyte that can be determined with
acceptable precision and accuracy. The LOQ was found
by analyzing a set of mobile phase and plasma standards
with a known concentration of FB.
Matrix effect
To predict the variability of matrix effects in samples
from individual subjects, matrix effect was quantified by
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follows:
Matrix Factor ¼
Peak response ratio in presence
of extracted matrix post extractedð Þ
Peak response ratio in aqueous standards
Six lots of blank biological matrices were extracted
each in triplicates and post spiked with the aqueous
standard at the Low,High QC level, and compared with
aqueous standards of same concentration. The overall
precision of the matrix factor is expressed as coefficient
of variation (CV %) and %CV should be < 15%.
Calibration curve, precission and accuracy
The calibration curve was constructed using values ran-
ging from 1.00 to 8000.00 ng/mL of FB in human
plasma. Calibration curve was obtained by linear model
with weighted 1/x2 regression analysis. The ratio of FB /
FBD7 peak area was plotted against the ratio of FB con-
centration in ng/mL. Calibration curve standard samples
and quality control samples were prepared in replicates
(n = 6) for analysis. Precision and Accuracy for the back
calculated concentrations of the calibration points,
should be within ≤15 and ± 15% of their nominal values.
However, for LLOQ, the Precision and Accuracy should
be within ≤ 20 and ± 20%.
Stability (Freeze - thaw, Auto sampler, Bench top, Long
term) of FB in plasma
Low quality control and high quality control samples
(n = 6) were retrieved from a deep freezer after three
freeze-thaw cycles according to the clinical protocol.
Samples were stored at −30°C in three cycles of 24, 36
and 48 hr. In addition, the long-term stability of FB in
quality control samples was also evaluated by analysis
after 55 days of storage at −30°C. Autosampler stability
was studied following 71.5 hr storage period in the
autosampler tray with control concentrations. Bench
top stability was studied for 24.5 hr period with control
concentrations. Stability samples were processed and
extracted along with the freshly spiked calibration
curve standards. The Precision and Accuracy for the
stability samples must be ≤ 15 and ± 15% respectively of
their nominal concentrations.
Study subjects
The study was carried out in accordance with the current
revision of the Declaration of Helsinki concerning medical
research in humans. Study protocol was approved by IEC
(Institutional Ethics committee) as per DCGI (Drug con-
trol general of india). Fourteen healthy male subjects, were
included in the pilot study. All volunteers gave a written
informed consent prior to participation, after they had
been informed of the nature and details of the study whichthey thoroughly understood. Subject screening exami-
nations were performed by a study. Clinician at acron
accunova manipal center. All clinical laboratory tests were
performed by the ISO 15189 certified laboratories, Depart-
ment of Pathology, acron accunova manipal Bangalore.
The daily results of the clinical laboratory tests including
the quality control data were verified by its own independ-
ent quality assurance personnel before reporting.
Subject inclusion criteria included Indian male, aged
between 18–45 years, no consumption of drugs or food
supplements for 4 weeks prior to the study, and no par-
ticipation in any bioavailability or bioequivalence study
at least 30 days prior to the present study.
The exclusion criteria included history of hypersensi-
tivity to Febuxostat and/or related chemical structure
and/or any of the components of the product, history or
concurrent symptoms of cardiovascular, liver, kidney,
gastrointestinal or hematological disorders and/or any
disease that might affect the bioavailability of drug, sub-
jects with malignancy, AIDs, allergy, vital sign abnormal-
ities, or clinically significant abnormal values during pre-
study screening, smoker (>10 cigarettes/day) or smoker
of < 10 cigarettes/day who could not quit at least 7 days
before study and throughout study (including washout
period), regular alcohol consumption (more than 1 time/
week) or alcohol consumption within 7 days prior to the
study, coffee consumption within past 7 days, and drug
addiction.Study design
The study was conducted as an open label, randomized
two-period, two-sequence, single-dose crossover bio-
equivalence study under fasting condition, and a wash-
out period of 7 days. All subjects arrived at the clinical
research laboratory, at least 12 h prior to the start of the
study. They were housed in an air-conditioned facility
and were given a standard dinner, which was finished
at least 10 h before dosing in each period of the study.
On the day of drug dosing in period 1, volunteers were
randomly assigned to one of two treatment sequences
(TR (sequence 1) or RT (sequence 2)), as indicated in a
pre-printed randomization scheme, which was generated
using block randomization with the blocks of size 4 and
6, and the allocation ratio of 1:1. Subjects in sequence 1
received treatment T at the first dosing period and then
crossed over to receive treatment R at the second dosing
period (after the 7-day washout period). Subjects in se-
quence 2 received treatments in the order of R and T at
the two dosing periods. The subjects were administered
the assigned Febuxostat formulation with 240 mL of
plain drinking water. After the intake of the study for-
mulations, the oral cavity was checked to ensure com-
pletion of the administration process. Subjects were
Figure 3 Chromatogram of blank human plasma.
Figure 2 Mass spectra of (A) Febuxostat parent ion, (B) Febuxostat product ion, (C) Febuxostat-d7 parent ion and (D) Febuxostat-d7
product ion.
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1.00 1.02 0.03 2.72 102.20
2.00 1.93 0.12 5.99 96.50
20.00 19.46 0.45 2.32 97.30
100.00 98.50 1.87 1.90 98.50
200.00 209.80 4.22 2.01 104.90
400.00 411.20 15.33 3.73 102.80
1200.00 1222.00 14.83 1.21 101.83
2400.00 2390.00 62.05 2.60 99.58
3600.00 3592.00 67.60 1.88 99.78
6000.00 5932.50 125.19 2.11 98.88
8000.00 7813.33 132.66 1.70 97.67
Figure 4 LLOQ Chromatograms of Febuxostat and Febuxostat-d7.
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after dosing.
No meal was permitted until 4 h after dosing. Drin-
king water was restricted from 1 h before dosing till 2 h
after dosing and ad libitum thereafter. Excess water in-
take (> 100 mL/h) was not permitted. Lunch, snacks,
and dinner were served as per the scheduled time. All
subjects abstained from any xanthine-containing food or
beverages for at least 72 h and alcoholic products for at
least 7 days prior to formulation administration and
throughout the sampling schedule during each period.
They were informed not to take any drug at least 30 days
prior to the study, especially phenobarbital, rifampicin
or gemfibrozil. Subjects abstained from the use of
tobacco- or nicotine-containing products for 7 days
prior to dosing and during confinement in the clinical
research laboratory. No concomitant medication was
permitted during the study period.
Blood sampling
Blood samples were collected as the pre-dose (0) hr
5 minutes prior to dosing followed by further samples at
0.167, 0.25, 0.333, 0.5, 0.75, 1, 1.33, 1.667, 2, 2.5, 3, 4, 5, 6,
8, 10, 12, 14, 18, 24, 30 and 36.0 hours. After dosing2.5 mL blood was collected each time in vaccutainers
containing K2EDTA. A total of 44 (23 time points for Re-
ference, 23 time points for Test) time points were col-
lected by using centrifugation 3200 rpm, 10°C, 10 min and
stored below −30°C until sample analysis.Test and Refe-
rence Febuxostat tablets were administered to same hu-
man volunteers under fasting conditions separately with





Concentration measured CVa (%) Accuracy
%
Concentration measured CV.a (%) Accuracy %
(n = 6) (n = 30)
(ng/mL) (ng/mL)
(mean ± S.d.) (mean ± S.D.)
1.00 0.98 ± 0.04 3.88 98.43 1.03 ± 0.09 8.44 103.19
3.00 2.92 ± 0.11 3.68 97.33 3.02 ± 0.17 5.57 100.78
4000.00 3957.78 ± 104.45 2.64 98.94 4021.78 ± 117.78 2.93 100.54
4800.00 4754.29 ± 158.36 3.33 99.05 4814.48 ± 133.07 2.76 100.30
a(Standard deviation/mean concentration measured)x100.
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Randomized, 2-way crossover) approved by IEC. During
the sample collection, all subjects were under medical
supervision. Vital signs were examined at scheduled time
as described in the protocol.
Tolerability assessments
Throughout the study, subjects were monitored by a
clinician, a clinical pharmacist, and 4 nurses. Tolerability
was determined by monitoring of vital signs (sitting
blood pressure, heart rate, and axillary body tem-
perature), and physical examinations at baseline and at
the end of each study period. Subject interviews were
also conducted regarding the potential occurrence of
adverse events (AEs) at each Febuxostat study period.
Serious AEs (SAEs) were considered to be when the sub-
ject outcome was death, life threatening, requiring
hospitalization, leading to disability, or requiring medical
intervention to prevent permanent impairment or dam-
age. All AEs and SAEs were recorded in the source data
record and on the case-report form, and their relation-
ship to the study drug was determined by the stu-
dy physician who was blinded to the randomization
schedule.
Pharmacokinetics and statistical analysis
Pharmacokinetics parameters from the human plasma














(n = 6) (n = 6)
(ng/mL) (ng/mL)
(mean ± S.D) (mean ± S.D)
3.00 3.09 ± 0.16 5.26 3.11 ± 0.12
4800.00 5034.29 ± 62.49 1.24 4800.00 ± 104.74
a (Standard deviation/mean concentration measured)X100.model using WinNon-Lin5.0. software (Pharsight, USA).
Blood samples were taken for a period of 3 to 5 times the
terminal elimination half-life (t1/2) and it was considered
as the area under the concentration time curve (AUC) ra-
tio higher than 80% as per FDA guidelines. Plasma FB
concentration-time profiles were visually inspected, and
Cmax and Tmax values were determined. The AUC0–t was
obtained by the trapezoidal method. AUC0–∞ was cal-
culated up to the last measureable concentration and ex-
trapolations were obtained using the last measureable
concentration and the terminal elimination rate constant
(Ke) it was estimated from the slope of the terminal expo-
nential phase of the plasma of the FB concentration-time
curve (by means of the linear regression method). The ter-
minal elimination half-life (t1/2), was then calculated as
0.693/Ke. Regarding AUC0–t, AUC0–∞ and Cmax bioequiva-
lence were assessed by means of analysis of variance
(ANOVA) and calculating the standard 90% confidence
intervals (90% CIs) of the ratio's test/reference (logarith-
mically transformed data). The bioequivalence was consi-
dered when the ratio of averages of log transformed data
was within 80-125% for AUC0–t, AUC0–∞ and Cmax (Guid-
ance for industry 2002; Guidance for industry 2003).
Results and discussion
Method development
LC-MS/MS has been used as one of the most powerful
analytical tools in clinical pharmacokinetics for itsle stability Long term stability Freeze and thaw stability













(%)(n = 6) (n = 6)
(ng/mL) (ng/mL)
(mean ± S.D) (mean ± S.D)
4.00 3.03 ± 0.08 2.56 3.04 ± 0.16 5.11
2.18 4800.80 ± 172.50 3.59 4923.81 ± 148.20 3.01
Table 4 Mean pharmacokinetic parameters of febuxostat
in 14 healthy volunteers after oral administration of





AUC0-t (ng · h/ml) 13774.96 14367.34
Cmax (ng/mL) 3065.46 3726.09
AUC0-∞ (ng · h/ml) 13872.24 14469.30
Kel (h_1) 0.09983 0.10996
Tmax (h) 1 1
AUC0—∞: area under the curve extrapolated to infinity;
AUC0—t: area under the curve up to the last sampling time;
Cmax: the maximum plasma concentration;
Tmax: the time to reach peak concentration;
Kel: the apparent elimination rate constant.
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this work is to develop and validate a simple, sensitive,
rapid, rugged and reproducible assay method for the
quantitative determination of FB from human plasma
samples. Chromatographic conditions, especially the
composition and nature of the mobile phase, usage of
different columns, different extraction methods such as
solid phase, Precipitation, Liquid-liquid extraction
methods were optimized through several trials to
achieve the best resolution and increase the signal of FB
and FBD7. The MS optimization was performed by dir-
ect infusion of solutions of both FB and FBD7 into the
ESI source of the mass spectrometer. Product ion
spectrum for FB and FBD7 yielded high-abundance frag-
ment ions of m/z 261.1 and m/z 262.1 respectively (Fig-
ure 2A,D). After mass spectrometer parameters
optimized, chromatographic conditions such as mobile
phase optimization, column optimization, extraction
method optimization was performed to obtain a fast and
selective LC method. A good separation and elution
were achieved using 10 mM Ammonium formate:
Acetonitrile (20:80 v/v) as the mobile phase, at a flow-
rate of 0.8 mL/min and injection volume of 5 μL.
Ascentis Express C18 (50x4.6 mm, 3.5 μ) column and
Liquid liquid extraction method was optimized for the
best chromatography.Method validation
The developed method was validated over a linear con-
centration range 1.00-8000.00 ng/mL. The validation pa-
rameters include Selectivity and Specificity, Limit of
Detection (LOD) and Quantification (LOQ), Matrix effect,
Precision and Accuracy, Recovery, Stability (Freeze - thaw,
Auto sampler, Bench top, Long term) was evaluated under
validation section (Guidance for industry 2001).Figure 5 Mean plasma concentrations of Test vs Reference
after 80 mg dose(one 80 mg tablet) in 14 healthy volunteers.Selectivity and specificity
The analysis of FB and FBD7 using MRM (Multiple
reaction monitoring) function was highly selective with
no interfering compounds (Figure 3).Chromatograms
obtained from plasma spiked with FB (1.00 ng/mL) and
FBD7 (1000.00 ng/mL) are shown in Figure 4.
Limit of detection (LOD) and quantification (LOQ)
The limit of detection was used to determine the instru-
ment detection levels for FB even at low concentrations.
5 μL of a 0.5 pg/mL solution was injected and estimated
LOD was 2.5 fg with S/N values ≥ 3–5.
The limit of quantification for this method was proven
as the lowest concentration of the calibration curve
which was proven as 1.00 ng/mL.
Matrix effect
Six lots of blank biological matrices were extracted each
in triplicates and post spiked with the aqueous standard
at the mid QC level, and compared with neat standards
of same concentration in alternate injections. The overall
precision of the matrix factor is 5.67 for Febuxostat.
There was no ion- suppression and ion- Enhancement
effect observed due to IS and analyte at respective reten-
tion time.
Precision and accuracy
Calibration curves were plotted as the peak area ratio
(FB/FBD7) versus (FB) concentration. Precision and Ac-
curacy of Calibration curve standards, Quality control
standards represented in Tables 1 and 2.Table 5 Test/Reference values for Log-transformed
pharmacokinetic parameters of febuxostat after
administration of 80 mg (1x80 mg) of test and reference
products in 14 healthy male volunteers
Pharmacokinetic parameters Cmax AUC0-t AUC0 - ∞
Test/Ref 82.27 95.88 95.87
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The recovery following the sample preparation using
Liquid-liquid extraction with Methyl tertiary butyle ether
was calculated by comparing the peak area of FB in
plasma samples with the peak area of solvent samples
and was estimated at control levels of FB. The recovery
of FB was determined at three different concentrations
3.0, 4000.0 and 4800.0 ng/mL were found as 80.05, 84.02
and 80.67% respectively. The overall average recovery
of FB and FBD7 were found to be 81.59 and 89.28%
respectively.
Stability (Freeze - thaw, Auto sampler, Bench top, Long
term)
Quantification of the FB in plasma subjected to three
freeze-thaw cycles (−30°C to room temperature), Auto-
sampler, Room temperature(Benchtop), Long term stabi-
lity details were shown in Table 3.
Application to biological samples
The above validated method was used in the determin-
ation of FB in plasma samples for establishing the bio-
equivalence of a single 80 mg dose (one 80 mg tablet) in
14 healthy volunteers. Typical plasma concentration ver-
sus time profiles is shown in Figure 5. All the plasma
concentrations of FB were within the standard curve re-
gion and retained above the 10.0 ng/mL (LOQ) for the
entire sampling period (Tables 4 and 5). The ANOVA
results revealed that period, sequence and treatment had
no statistically significant effects on Cmax, AUC0-tlast and
AUC0-∞. Since the sequence or carry-over effect was not
significant, the ANOVA test was valid. The statistically
significant subject within sequence effect on Cmax,
AUC0-tlast and AUC0-∞ were observed that are usually
seen in small sample size study as in crossed over phase
I and bioequivalence studies. Bioequivalence between the
80 mg immediate release tablet formulations of Febuxostat
under fasting condition was demonstrated by the 90% CI
of the geometric mean ratios of Cmax, AUC0-tlast and
AUC0-∞ lying within the acceptable criteria of 80-125%.
The test and reference formulations had very similar t1/2
at approximately 6.5 h. Period, sequence and treatment
had no significant effects on Cmax, AUC0-tlast and AUC0-∞.
Conclusion
The method described in this manuscript has been de-
veloped and validated over the concentration range of
1.00 - 8000.00 ng/mL in human plasma. The selectivity,
sensitivity, precision and accuracy obtained with this
method make it suitable for the purpose of the present
study. The simplicity of the method, and using rapid li-
quid–liquid extraction and sample turnover rate of
2.5 min per sample, make it an attractive procedure in
high-throughput bioanalysis of Febuxostat. The validatedmethod was successfully applied and demonstrated the
bioequivalence of the 80-mg immediate release tablet
formulation manufactured by APL Research center.,
India and the reference product Urolac® manufactured
by Takeda Pharmaceuticals, America,INC(USA) by oral
administration in 14 healthy human volunteers, and then
can be concluded that the two formulations can be used
interchangeably.
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